The World Health Organization just went on record to claim that ivermectin is “not an effective treatment for hantavirus,” fully dismissing the large body of research suggesting the opposite is likely true.

This is no surprise given thatBill Gates is now the WHO’s top funder and13 hantavirus vaccines and gene therapiesare under development:

Click here for an enlarged view

This rapid dismissal of a safe, cheap, widely available drug follows a now-familiar pattern. When health authorities immediately reject repurposed medicines with plausible mechanisms and real-world data against RNA viruses in favor of experimental “vaccines”, it often means that the opposite the true. We see this out with the dilemma of a rodent infested ship with hantavirus in the Atlantic Ocean where the WHO has 147 passengers locked down without access to early treatment kits.

Let’s look at the evidence forivermectinandchloroquine/hydroxychloroquineagainst hantavirus:

Since the early 2010s, researchers have documented ivermectin’s broad-spectrum antiviral activity against a wide range of RNA viruses, including dengue, Zika, West Nile, yellow fever, chikungunya, influenza, HIV, and SARS-CoV-2. These antiviral effects are summarized across dozens of studies in a2020 systematic review by Heidary et al.

The most compelling real-world evidence comes from its performance against COVID-19. The comprehensive real-time meta-analysis athttps://c19early.org/inow includes106 studies involving hundreds of thousands of patients. These studies consistently show strong benefits — particularly when used early or as prevention — with major reductions in mortality, hospitalization, and severe disease.

Crucially, hantaviruses are also RNA viruses — specifically negative-sense single-stranded RNA viruses. While they differ in structure and replication details from viruses like SARS-CoV-2, they still rely on host cell machinery and intracellular transport pathways that ivermectin is known to disrupt.

Mechanistically, ivermectin inhibits importin α/β nuclear transport, a pathway many RNA viruses exploit to shuttle viral proteins into the host cell nucleus to suppress antiviral responses. Hantavirus nucleocapsid (N) protein has been shown to interact with these same host pathways to interfere with immune signaling. By blocking this transport system, ivermectin may prevent the virus from disabling the host’s innate defenses.

In addition, ivermectin interferes with viral replication and assembly processes inside the cell, and exerts anti-inflammatory effects that could blunt the vascular leakage and lung injury characteristic of severe hantavirus disease.

Source: Global Research